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Background: We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast
cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.
Patients and methods: The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or
letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were deﬁned as: mucin-
ous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or
tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were
disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval
(DRFI). Median follow-up in the analytic cohort was 8.1 years.
Results:Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other
three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal
(88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year
rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup
of women with special histotypes, we observed a nonsigniﬁcant increase in the hazard of breast cancer recurrence with
letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% conﬁdence interval 0.94–11.7; P = 0.06].
Conclusions: Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other
histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histo-
types, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous
or tubular/cribriform disease.
Clinicaltrials.gov: NCT00004205.
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introduction
In recent years, appropriate adjuvant systemic therapies for op-
erable breast cancer have been tailored to individual patients.
Assessments of patient risk, co-morbidities, and patient prefer-
ence are considered together with features that predict better re-
sponse to therapy and better outcome [1–3].
However, less attention is paid to identifying special types of
breast cancers with a distinct morphology that exhibits a different
prognostic and predictive proﬁle compared with more common
histotypes, such as invasive ductal or lobular carcinomas, even
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with similar biological features and stages [4]. In particular, within
luminal breast cancer, several special histotypes display an ex-
tremely good prognosis, often approaching or equaling that of
the general population [5, 6]. Histotypes with good prognosis
include: pure tubular carcinoma, a rare histology accounting for
<2% of invasive breast cancer and with an excellent prognosis
[7, 8]; cribriform carcinoma, which also has a very favorable
prognosis irrespective of lymph node metastases [8, 9]; and pure
mucinous breast carcinoma, representing 1%–4% of all breast
cancers. If present in pure form, this histotype predicts a
10-year survival >90% [10, 11].
Limited results are available on the outcomes of these rare histo-
types according to the adjuvant treatment received. Consequently,
no information from retrospective analyses is available for tailoring
adjuvant treatment of an individual patient with these special
histotypes.
We investigated the outcomes of postmenopausal women with
hormone receptor-positive (HR+), early invasive breast cancer
with special tumor histotypes (mucinous, tubular, or cribriform)
who were enrolled in the monotherapy cohort of the BIG 1-98
trial, and the relationship between outcomes and other biological
or treatment characteristics.
patients andmethods
The design and conduct of the BIG 1-98 trial have been described elsewhere
[12, 13].
This analysis was based on the BIG 1-98 at 8.7 years median follow-up
[14]. The analytic cohort for this analysis included women randomized to 5
years of tamoxifen or letrozole monotherapy whose tumors were centrally
reviewed (n = 4091) (Figure 1). Histotypes considered in this analysis were
mucinous (n = 87) or mucinous variant (n = 13), tubular (n = 71), or tubular
variant (n = 3), and cribriform pure (n = 4) or mixed (n = 5) [15]. Mucinous
and mucinous variants were combined into the ‘mucinous’ group, and
tubular and cribriform types were combined into the ‘tubular/cribriform’
group (Figure 1). The histotypes studied included 183 patients with either
mucinous or tubular/cribriform tumors, 4.4% of the analytic cohort. Ninety-
six women were randomized to letrozole and 87 to tamoxifen. Comparator
histologic groups were ductal and other histotypes: 406 with lobular hist-
ology, 234 with other classiﬁcations, and 11 with missing histology. Luminal
A was deﬁned as HR+, HER2-negative, and Ki-67 <14%; luminal B as HR+,
HER2-negative, and Ki-67 ≥14% [16].
The tamoxifen group included 24 women (28%) who selectively crossed
over to letrozole after the ﬁrst interim efﬁcacy results of the trial were
released in 2005. Follow-up for these women was censored at the time of the
selective crossover, reducing the median follow-up of the special histotype
group (n = 183) to 8.1 years. No outcome events were lost as a result of
the censoring.
All participants provided written informed consent. Ethics committees
and relevant health authorities approved the protocol.
statistical analysis
All patients were analyzed according to randomized treatment. Comparisons
of baseline disease, demographic, and prior treatment characteristics used
Fisher’s exact test for categorical variables and Wilcoxon rank-sum or
Kruskal–Wallis tests for continuous characteristics. Four time-to-event out-
comes are presented: disease-free survival (DFS), overall survival (OS), breast
cancer-free interval (BCFI), and distant recurrence-free interval (DRFI).
DFS was deﬁned as the time from randomization to the earliest invasive
breast recurrence, new invasive breast cancer in the contralateral breast, any
second (nonbreast) malignancy, or death from any cause. OS was deﬁned as
the time from randomization to death from any cause. BCFI was deﬁned as
the time from randomization to the earliest invasive breast recurrence or
new invasive breast cancer in the contralateral breast. DRFI was deﬁned as
the time from randomization to the earliest distant metastases. For BCFI and
DRFI, deaths without prior cancer events were censored. Comparisons of
survival distributions were made using the log-rank test. Cox proportional
hazards (PH) models, stratiﬁed by randomization option (two-arm/four-
arm) and chemotherapy, were used to estimate hazard ratios (HRs) and 95%
conﬁdence intervals (CIs). Univariate Cox PH models included only treat-
ment as a predictor.
Multivariable Cox PH models were ﬁt to each outcome to assess import-
ant predictors. Candidate predictors in each model were: histology, tumor
grade and size, subtype (luminal A or B, missing/other ER+), nodal status
(N0/Nx, N+), and local therapy as the combination of radiotherapy (RT)
and either mastectomy (MTX) or breast-conserving surgery (BCS) (BCS/RT,
BCS/no RT, MTX/RT, MTX/no RT). Age divided at the sample median
8010 women randomized
4922 randomized
to T or L for 5 years
3088 randomized to
LÆT or TÆL
4091 had central
review of histology
831 had no central
review of histology
1637 Letrozole
1620 Tamoxifen
3257 ductal 100 mucinous
55 Letrozole
45 Tamoxifen
83 tubular or
cribriform
41 Letrozole
42 Tamoxifen
651 other
histologies
323 Letrozole
328 Tamoxifen
Figure 1. Patients from the BIG 1-98 trial included and excluded in this study according to treatment group and availability centrally reviewed histology.
Other histologies were 651 (15.9%): 406 lobular/ 234 other/11 missing. L, letrozole; T, tamoxifen.
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(≤64 years, >64 years) was included in models of DFS, BCFI, and DRFI. The
OS model was stratiﬁed additionally by age. Two-way interactions between
histology and treatment were included among model predictors to explore if
the effect of treatment varied according to histology.
HRs and P values for the forest plot were estimated from the interaction
of treatment and histology based on the univariate Cox PH model. P values
for Cox PH models are from the Wald χ2 test. Statistical signiﬁcance is
deﬁned as P < 0.05; there are no corrections for multiple comparisons.
results
Baseline and prior treatment characteristics are shown accord-
ing to histology in Table 1. Treatment assignment (letrozole or
tamoxifen) was balanced between the histotypes.
outcome according to histology
Women with mucinous or tubular/cribriform tumors had charac-
teristics of lower risk diseases compared with those with ductal or
other histologies. Mucinous or tubular/cribriform tumors were
more often characterized as luminal A, Ki-67 <14%, and no evi-
dence of peritumoral vascular invasion. The tumors tended to
be grade 1 with most measuring 2 cm or less. The majority of
women with mucinous or tubular/cribriform histotypes were
treated with RT with either breast-conserving surgery or mastec-
tomy, and most had node-negative disease. Only 15 patients
received chemotherapy as a part of their adjuvant or neoadjuvant
treatment; therefore, the majority of women with mucinous or
tubular/cribriform histologies (n = 168, 91.8%) received only tam-
oxifen or letrozole as adjuvant systemic therapy.
Patients with mucinous tumors had a higher proportion of
luminal B disease (HER2-negative) (23%) compared with those
with tubular/cribriform (4.8%); the proportion with luminal A
disease with mucinous tumors was 64.0% compared with 81.9%
with tubular/cribriform. Women with mucinous tumors were
signiﬁcantly older than women in the other histologies (median
age: 69 versus 62).
Distributions and 5-year Kaplan–Meier estimates of outcomes
for the four histology groups are summarized in Figure 2.
Overall, women with tubular/cribriform tumors showed the best
outcomes compared with those in the other three histologic
groups. Women with mucinous carcinoma had comparable DFS
and OS to women with ductal or other histotypes. Five-year re-
currence rates were higher in patients with tubular/cribriform
(97.5%) or mucinous (93.5%) disease than in patients with
ductal (88.9%) or other histotypes 89.9%, P = 0.03). Women with
mucinous or tubular/cribriform carcinoma had better DRFI (5-
year DRFI: 97.8%, 98.8%, respectively) than those with ductal
(90.9%) or other (92.1%) (P = 0.002) carcinomas.
outcome according to treatment (letrozole versus
tamoxifen)
The median age at randomization was 65 and 64 years in the
letrozole and tamoxifen arms, respectively. Women assigned to
tamoxifen more often had N0/Nx disease (82% tamoxifen, 71%
letrozole) or grade 1 tumors (76% tamoxifen, 66% letrozole). A
lower percentage of patients in the tamoxifen group received
neoadjuvant or adjuvant chemotherapy (3% tamoxifen, 11.5%
letrozole); however, none of these differences were statistically
signiﬁcantly different.
The 5-year DFS estimates (±standard error of the estimate)
were 83.2 ± 3.8% for patients in the letrozole group versus
94.9 ± 2.5% for those in the tamoxifen group (Figure 3A),
whereas the 5-year OS estimates were 93.7 ± 2.5% versus
97.3 ± 1.9% (Figure 3B). Among patients receiving tamoxifen,
the only distant recurrence occurred at ∼72 months of follow-
up. As a result, 5-year estimates of DRFI were 100% in the tam-
oxifen group and 96.8 ± 1.8% in the letrozole group (Figure 3C).
No recurrences were reported for the ﬁrst year of follow-up in
either treatment group.
When the effect of treatment upon outcomes was evaluated
by univariate models, only BCFI showed a difference between
letrozole and tamoxifen: the hazard of recurrence was 3.3 times
higher among women receiving letrozole and was marginally
signiﬁcant [HR (letrozole versus tamoxifen) 3.31, 95% CI 0.94–
11.7, P = 0.06]. This ﬁnding was upheld by the multivariable
Cox PH model [HR (letrozole versus tamoxifen) 3.54, 95% CI
0.96–13.1, P = 0.06].
The sites of ﬁrst recurrence were: local–regional and contralat-
eral in 6.3% of patients in the letrozole group and 2.2% in the
tamoxifen group; distant in 4.1% in the letrozole group and
1.1% in the tamoxifen group.
outcomes according to treatment and histotype
The relative effects of letrozole and tamoxifen were investigated
according to the two histologic groups (mucinous versus tubular/
cribriform). Looking at the four histotype-treatment combina-
tions, patients with mucinous carcinoma treated with letrozole
appeared to have the worst outcomes. In contrast, outcomes for
patients with mucinous carcinoma treated with tamoxifen were
similar to that of patients with tubular/cribriform, suggesting that,
in these histotypes, the beneﬁt of letrozole over tamoxifen is less
clear than in ductal or other histologies (supplementary Figure S1,
available at Annals of Oncology online). However, the HR (letro-
zole versus tamoxifen) did not reach statistical signiﬁcance for any
of the four outcomes considered (Table 2).
comparisons of treatment effects for histotype
The forest plot summarizes the effects of treatment overall and
in each of four subgroups based on univariate models (Figure 4).
Overall, letrozole has signiﬁcantly greater efﬁcacy than tamoxi-
fen for all four end points. The superiority of letrozole is less
clear in the rare histotypes. The HR estimates tend to favor tam-
oxifen for all four end points in the mucinous and tubular/crib-
riform groups, but the CIs are too wide to draw any conclusions
favoring tamoxifen.
discussion
The present analysis provides an opportunity to study very rare
histotypes that have been centrally evaluated and treated and fol-
lowed uniformly within a large clinical trial. Others have reported
the favorable prognosis of these histotypes, but there are no pub-
lished reports about differential beneﬁts of endocrine therapy.
Our report suggests that mucinous, tubular, and cribriform
histotypes have a more favorable prognosis compared with
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Table 1. Patient demographic, disease, and prior treatment characteristics by histology
Characteristic Overall
(N = 4091)
Histology P value
(4 histologies)
P-value (mucinous versus
tubular/cribriform)Ductal
(N = 3257)
Mucinous
(N = 100)
Tubular or
cribriform
(N = 83)
Other
histology
(N = 651)
Age at enrollment (years)
Median (range)
62
(38–86)
62
(38–86)
69
(49–84)
62
(45–81)
62
(39–84)
<0.0001 <0.0001
N % N % N % N % N %
Subtype <0.0001 0.003
Luminal A 1885 46.1 1422 43.7 64 64.0 68 81.9 331 50.8
Luminal B (HER2-negative) 1571 38.4 1374 42.2 23 23.0 4 4.8 170 26.1
Unknown 537 13.1 391 12.0 11 11.0 9 10.8 126 19.4
Other ER+ 98 2.4 70 2.1 2 2.0 2 2.4 24 3.7
ER present/absent <0.0001 0.99
Absent 63 1.5 54 1.7 – – – – 9 1.4
Present 3554 86.9 2866 88.0 89 89.0 74 89.2 525 80.6
Unknown 474 11.6 337 10.3 11 11.0 9 10.8 117 18.0
PgR present/absent <0.0001 0.35
Absent 433 10.6 341 10.5 4 4.0 8 9.6 80 12.3
Present 3186 77.9 2584 79.3 83 83.0 65 78.3 454 69.7
Unknown 472 11.5 332 10.2 13 13.0 10 12.0 117 18.0
HER2 status <0.0001 0.99
Negative 3410 83.4 2731 83.9 88 88.0 74 89.2 517 79.4
Positive 257 6.3 234 7.2 1 1.0 – – 22 3.4
Unknown 424 10.4 292 9.0 11 11.0 9 10.8 112 17.2
Ki-67 ≥14 <0.0001 0.001
No 1979 48.4 1500 46.1 64 64.0 69 83.1 346 53.1
Yes 1560 38.1 1369 42.0 23 23.0 4 4.8 164 25.2
Unknown 552 13.5 388 11.9 13 13.0 10 12.0 141 21.7
Nodal status <0.0001 0.40
N0/Nx 2371 58.0 1847 56.7 79 79.0 60 72.3 385 59.1
1–3 positive 1211 29.6 1003 30.8 15 15.0 19 22.9 174 26.7
4+ positive 506 12.4 405 12.4 6 6.0 4 4.8 91 14.0
Unknown 3 0.1 2 0.1 – – – – 1 0.2
Peritumoral vascular invasion <0.0001 0.50
No 3653 89.3 2877 88.3 97 97.0 83 100.0 596 91.6
Yes 389 9.5 358 11.0 2 2.0 – – 29 4.5
Unknown 49 1.2 22 0.7 1 1.0 – – 26 4.0
BRE grade <0.0001 <0.0001
1 803 19.6 631 19.4 48 48.0 81 97.6 43 6.6
2 2279 55.7 1750 53.7 48 48.0 1 1.2 480 73.7
3 904 22.1 854 26.2 4 4.0 – – 46 7.1
Unknown 105 2.6 22 0.7 – – 1 1.2 82 12.6
Tumor size <0.0001 <0.0001
≤2 cm 2527 61.8 2063 63.3 50 50.0 72 86.7 342 52.5
2–5 cm 1376 33.6 1088 33.4 43 43.0 8 9.6 237 36.4
>5 cm 158 3.9 90 2.8 7 7.0 2 2.4 59 9.1
Unknown 30 0.7 16 0.5 – – 1 1.2 13 2.0
Adjuvant/neoadjuvant chemo <0.0001 0.99
No 3170 77.5 2519 77.3 92 92.0 77 92.8 482 74.0
Yes 921 22.5 738 22.7 8 8.0 6 7.2 169 26.0
Local therapy <0.0001 0.0007
BCS/RT 2075 50.7 1706 52.4 41 41.0 58 69.9 270 41.5
BCS/no RT 134 3.3 104 3.2 5 5.0 5 6.0 20 3.1
Mastectomy/RT 761 18.6 577 17.7 14 14.0 6 7.2 164 25.2
Mastectomy/no RT 1115 27.3 867 26.6 39 39.0 14 16.9 195 30.0
Unknown 6 0.1 3 0.1 1 1.0 – – 2 0.3
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other histotypes. Similar favorable outcomes have been reported
in the literature. In a series of 111 patients with tubular breast
cancer, the locoregional recurrence rate was low (<1%) and no
patient developed distant metastases [17]. Likewise, in a series of
102 patients, none of the patients with tubular carcinoma devel-
oped distant metastasis or died from breast cancer [18]. The sur-
vival of patients with tubular carcinoma is similar to the general
population, and there is no evidence that adjuvant therapy inﬂu-
ences survival, even if sentinel node biopsy is positive [19].
Tubular carcinoma also has a favorable long-term prognosis,
even if axillary nodes were involved; thus, nodal status may not
be an indicator of poor outcome [20].
Our results also suggest that tamoxifen may be a treatment
choice for women with these histotypes. The overall beneﬁt of
letrozole over tamoxifen observed in ductal or other histologies
was not as strong in the special histotypes, although based on a
limited number of events. Patients with mucinous carcinoma
treated with letrozole had the worst outcome among the groups
studied. In contrast, outcomes for patients with mucinous
disease who were treated with tamoxifen were similar to those
with tubular/cribriform breast cancer. Side-effect proﬁle and
patient preference should guide the choice of adjuvant endo-
crine treatment of women with these histologies.
It should be noted that patients in our study with special histo-
types had lower risk characteristics (72% had luminal A).
Mucinous, tubular, and cribriform histotypes are found among
luminal A cancers more than in other histotypes [16, 21]. In our
series, patients with tubular and cribriform histotypes were more
frequently classiﬁed as luminal A, while patients with mucinous
breast cancer had a greater proportion with luminal B (HER2-
negative). The lower risk disease in our study sample contributed
to small numbers of outcome events, especially for BCFI or
DRFI, which could inﬂuence the power of our multivariable
models to ﬁnd factors associated with outcome.
Adjuvant therapy with aromatase inhibitors provides, on
average, superior outcomes to tamoxifen for postmenopausal
women with endocrine-responsive early breast cancer; however,
data from BIG 1-98 suggest that, in low-proliferating tumors,
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Figure 2. Kaplan–Meier estimates of disease-free survival (DFS, A), overall survival (OS, B), breast cancer-free interval (BCFI, C), and distant recurrence-free
interval (DRFI, D) according to histotype for the 4091 patients in the analytic cohort.
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Figure 3. Kaplan–Meier estimates of disease-free survival (DFS, A), overall survival (OS, B), breast cancer-free interval (BCFI, C), and distant recurrence-free
interval (DRFI, D) according to randomly assigned treatment group for the cohort of 183 patients with mucinous, tubular, or cribriform histotypes.
Table 2. Univariate and multivariable Cox models results for patients with special histotypes
DFS Hazard ratio
(Let versus Tam)
(95% CI)
Univariate Cox PH model Multivariable Cox PH model
Mucinous Tub/crib Mucinous Tub/crib
1.49 (0.7–3.3) 1.06 (0.4–3.1) 1.52 (0.7–3.5) 1.05 (0.3–3.1)
Interaction P value (treatment by histology) 0.62 0.59
OS Hazard ratio
(Let versus Tam)
(95% CI)
Univariate Cox PH model Multivariable Cox PH model
Mucinous Tub/crib Mucinous Tub/crib
1.28 (0.5–3.3) 0.67 (0.2–2.7) 1.04 (0.4–2.8) 0.64 (0.1–3.0)
Interaction P value (treatment by histology) 0.45 0.60
BCFI Hazard ratio
(Let versus Tam)
(95% CI)
Univariate Cox PH model Multivariable Cox PH model
Mucinous Tub/crib Mucinous Tub/crib
3.39 (0.7–15.8) 3.11 (0.4–28.0) 4.47 (0.9–22.4) 2.43 (0.2–24.0)
Interaction P value (treatment by histology) 0.95 0.67
DRFI Hazard ratio
(Let versus Tam)
(95% CI)
Univariate Cox PH model Multivariable Cox PH model
Mucinous Tub/crib Mucinous Tub/crib
2.01 (0.2–19.5) Not defineda 9.7 (0.3–300) Not defineda
Interaction P value (treatment by histology) 0.99 0.99
aThere were no DRFI events in the tamoxifen arm.
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the magnitude of letrozole beneﬁt versus tamoxifen might not
be as large as in more highly proliferative tumors [22, 23], thus
suggesting a similar treatment beneﬁt in luminal A tumors. In
general, in the current analysis, patients with rare histologies
and luminal B (HER2-negative) disease had a threefold increase
in the hazard of death compared with luminal A disease.
One possible explanation of the better outcome of these histo-
types may be found in their genomic expression. Cribriform and
tubular carcinomas usually display similar immunophenotypes
and are characterized by similar types and patterns of genetic
aberrations, commonly found in most low-grade luminal-type
breast carcinomas [10, 24, 25]. However, signiﬁcant differences
were detected and validated by quantitative reverse transcriptase
PCR, which may in part explain the reported, more favorable
outcome of cribriform/tubular [8]. Some authors also suggest
that tubular and cribriform carcinomas have similar clinical pres-
entation, natural history, and are probably associated with the
same family of precursor and preinvasive lesions [5, 26], thus in-
dicating a common etiological background or the involvement of
common genetic pathways during carcinogenesis [25].
In conclusion, patients with rare histologies treated with 5 years
of letrozole or tamoxifen in the BIG1-98 trial had better outcomes
than other histologies. The magnitude of the letrozole advantage
compared with tamoxifen seen in the overall population was not
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Figure 4. Proportional hazards model results of disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-
free interval (DRFI) in histology subgroups. Hazard ratios and P values were estimated from the interaction of treatment and histology based on the univariate
Cox PH model. There were no events in the tamoxifen arm for tubular or cribriform DRFI, so this comparison is not included in the forest plot.
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observed in patients with mucinous or tubular/cribriform disease.
For these rare histologies, our data suggest that tamoxifen could be
a reasonable treatment option.
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